Array BioPharma Inc. (NASDAQ:ARRY) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Stock Performance
Shares of Array BioPharma Inc. traded low $ -1.63 or -4.34 percent on Wednesday, reaching $ 35.94 with volume of 2.02 million shares. Array BioPharma Inc. has traded high as $ 37.49 and has cracked $ 34.13 on the downward trend
The closing price of $ 35.94, representing a 29.33 % increase from the 52 week low of $ 29.05 and a 15.46 % decrease over the 52 week high of $ 44.44.
The company has a market capital of $ 4.56 billion and is part of the Healthcare sector and Biotechnology industry.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The companys lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer.
